Written especially for nurses caring for patients
with cancer, the 2014 Oncology Nursing Drug Handbook
uniquely expresses drug therapy in terms of the nursing
process: nursing diagnoses, etiologies of toxicities,
and key points for nursing assessment, intervention, and
evaluation. Updated annually, this essential reference
provides valuable information on effective symptom
management, patient education, and chemotherapy
administration. Completely revised and updated, the 2014
Oncology Nursing Drug Handbook includes: * New chapter
on Chemobiotherapy for Noncancer Diseases * Specific
drugs described in terms of their mechanism of action,
metabolism, drug interactions, laboratory
effects/interference, and special considerations * The
most important and common drug side effects * Greater
discussion of fundamentals of malignant transformation,
new molecular targets, and drugs in the pipeline New
drug entries include: enzalutamide, omacetaxine
(Synribo), tbo-filgrastim (Netroval), ado-trastuzumab
emtansine, aflibercept, bosutinib, cabozantinib,
carfilzomib, dabrafenib, pomalidomide, ponatinib,
regorafenib, trametinib, abatacept (Orencia), adalimumab
(Humira), certolizumab pegol (CIMZA), etanercept
(Enbrel), golimumab (Simponi), infliximab (Remicade),
tocilizumab (Actemra), and tofacitinib (Xeljanz). |
|